Abstracts tagged "Epidemiologic methods"

Abstract Number: 1250 • 2016 ACR/ARHP Annual Meeting
Mortality in Indigenous Populations of Canada, the United States, Australia, and New Zealand with Rheumatic Disease: A Systematic Review
Kelle Hurd¹ and Cheryl Barnabe², ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Indigenous populations of Canada, America, Australia, and New Zealand share similar experiences of colonization impacting their rheumatic disease clinical outcomes. The objective of our…
Abstract Number: 3187 • 2016 ACR/ARHP Annual Meeting
Societal Costs and Patients’ Experience of Health Inequities from Psoriatic Arthritis: A Danish Cohort Study
Lars Erik Kristensen¹, Tanja S Jørgensen², Robin Christensen³, Henrik Gudbergsen⁴, Lene Dreyer⁵, Christine Ballegaard⁶, Lennart T.H. Jacobsson⁷, Vibeke Strand⁸, Philip J Mease⁹ and Jakob Kjellberg¹⁰, ¹Musculoskeletal Statistics Unit, The Parker Institute, Dept. of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen, Denmark, ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁴Knowledge Centre for Telemedicine and Departments of Rheumatology, Copenhagen University Hospitals, Glostrup, Frederiksberg and Bispebjerg, Frederiksberg, Denmark, ⁵Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁶The Parker institute, Copenhagen, Denmark, ⁷Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹University of Leeds, Leeds, United Kingdom, ¹⁰Danish Institute for Local and Regional Government Research, Copenhagen, Denmark, Copenhagen, Denmark
Background/Purpose: Psoriatic arthritis (PsA), a chronic inflammatory joint disorder typically affecting individuals with psoriasis of the skin, is associated with severe comorbidities, reduced quality of…
Abstract Number: 262 • 2016 ACR/ARHP Annual Meeting
Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013 Background/Purpose: Sarcoidosis is a multi-systemic disorder of unknown etiology. Studies of seasonal and regional…
Abstract Number: 1419 • 2016 ACR/ARHP Annual Meeting
Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients
Hervé Devilliers¹, Meenakshi Jolly², Maxime Samson³, Bernard Bonnotte⁴, Francois Maurier⁵, Pascal Sève⁶, Nadine Magy-Bertrand⁷, Denis Wahl⁸, Jean-Loup Pennaforte⁹, Thierry Martin¹⁰, Olivier Aumaître¹¹, Gilles Blaison¹², Philip Bielefeld¹³, Alexis Mathian¹⁴, Christine Binquet¹⁵ and Zahir Amoura¹⁴, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Dijon University Hospital, Dijon, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁶Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁷CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁸CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ⁹Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ¹⁰Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, ¹¹Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ¹²Internal medicine departement, Colmar Hospital, Colmar, France, ¹³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁵INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France
Background/Purpose: To assess validity and reliability of French LupusPRO in France. Methods: After cross-cultural adaptation and harmonization for France, the LupusPRO was administered along with…
Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting
Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort
Claire Deakin¹, Raquel Campanilho-Marques², Stefania Simou³, Elena Moraitis⁴, Eleanor Pullenayegum^5,6, Lucy R Wedderburn^4,7,8, Clarissa Pilkington⁹ and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ³Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁵Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting
Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Sarah Dyball¹ and Marwan Bukhari², ¹University Hospital South Manchester, Manchester, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
Abstract Number: 1505 • 2016 ACR/ARHP Annual Meeting
Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Sadao Jinno¹, Na Lu^2,3, S. Reza Jafarzadeh⁴ and Maureen Dubreuil^3,5, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁴Medicine, Washington University School of Medicine, St Louis, MO, ⁵Rheumatology, Boston VA HealthCare System, Boston, MA
Background/Purpose: With the increasing uptake of RA treatments that confer infection risk, an increase in the rates of infection hospitalizations among RA patients is expected,…
Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting
Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Stephanie J.W.Shoop^1,2, Kimme L. Hyrich^3,4, Suzanne M.M. Verstappen⁴, Wendy Thomson^5,6, Janet E. McDonagh⁷ and CAPS, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom
Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
Abstract Number: 1519 • 2016 ACR/ARHP Annual Meeting
How Much, and When, Does Autoimmune Thyroid Disease Increase the Risk of RA, and Does RA-Onset Impact the Risk of Autoimmune Thyroid Disease?
Kristin Waldenlind¹, Saedis Saevarsdottir¹, Camilla Bengtsson² and Johan Askling¹, ¹Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Environmental medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune thyroid disease (AITD) is one of the most common autoimmune diseases, and occurs more often than expected in patients with Rheumatoid Arthritis (RA).…
Abstract Number: 693 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis
Maren C. Karreman^1,2, Jolanda J. Luime³, Johanna M.W. Hazes² and Angelique E.A.M. Weel¹, ¹Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Inflammatory Bowel Disease (IBD) is a chronic disease that affects up to 0.5% of the population, comprising both Crohn’s Disease (CD) and ulcerative colitis…
Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Lauren Harter¹, Daniel Shin², Joshua F. Baker³, Junko Takeshita², Thorvardur Love^4,5, Joel Gelfand⁶ and Alexis Ogdie⁷, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵Landspitali University Hospital, Reykjavík, Iceland, ⁶University of Pennsylvania Health System , Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
Abstract Number: 836 • 2016 ACR/ARHP Annual Meeting
Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis
Antonia Valenzuela^1,2, Jessica K. Gordon³, Tatiana Sofia Rodriguez-Reyna⁴, Susanna Proudman^5,6, Murray Baron⁷, Monique Hinchcliff⁸, Dinesh Khanna⁹, Amber Young¹⁰, Flavia V. Castelino¹¹, Sara R. Schoenfeld¹², Virginia D. Steen¹³, David Fiorentino¹⁴ and Lorinda Chung¹⁵, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁵Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients. Repetitive trauma may be involved in the pathogenesis of…
Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson², Rodrigo Cartin-Ceba³, James A. Garrity⁴, Wendy M. Smith⁵, Ulrich Specks⁶, Eric L. Matteson¹ and Ashima Makol⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Ophthalmology, Mayo Clinic, Rochester, MN, ⁵Department of Ophthalmology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
Abstract Number: 46 • 2015 ACR/ARHP Annual Meeting
Feasibility Study of Smartphone Data Collection for Cloudy with a Chance of Pain: Sustained Engagement for Daily Self-Reporting of Disease Severity in Rheumatoid Arthritis over Two Months
Samuel Reade¹, Jamie C Sergeant^2,3, Matthew Sperrin⁴, David M. Schultz⁵, Karen Spencer⁶, Caroline Sanders⁶ and William G Dixon⁷, ¹The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁴Institute of Population Health, Health e-Research Centre, The University of Manchester, Manchester, United Kingdom, ⁵Faculty of Engineering and Physical Sciences, School of Earth, Atmospheric and Environmental Sciences, The University of Manchester, Manchester, United Kingdom, ⁶Institute of Population Health, Centre for Primary Care, The University of Manchester, Manchester, United Kingdom, ⁷Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Previous research has attempted to study the association between weather and joint pain. Inconclusive results may be due, in part, to infrequent measures of…
Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting
Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist¹, Tomas Jernberg², Solveig Wållberg-Jonsson³ and Johan Askling^4,5, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…

« Previous Page
1
…
7
8
9
10
11
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.